

## SEQUENCE LISTING

<110> LINTNER, KARL

<120> COMPOSITIONS CONTAINING MIXTURES OF TETRAPEPTIDES AND TRIPEPTIDES

<130> SEDERM 3.0-001

<140>

<141>

<150> PCT/FR03/03423

<151> 2003-11-17

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 1

Thr Lys Pro Arg

1

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 2

Arg Lys Pro Arg

1

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 3

Gly Gln Pro Arg  
1

<210> 4  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 4  
Ala Gln Thr Arg  
1

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<220>  
<223> see specification as filed for detailed description of lipid  
group attachments and preferred embodiments

<400> 5  
Lys Thr Thr Lys Ser  
1 5

<210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 6  
Tyr Gly Gly Phe  
1

<210> 7  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 7

Arg Gly Asp Ser

1

<210> 8

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 8

Arg Ser Arg Lys

1

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD\_RES

<222> (5)

<223> Met or Leu

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 9

Tyr Gly Gly Phe Xaa

1

5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 10

Val Gly Val Ala Pro Gly

1

5